BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ), referred to as “Mainz Biomed” or the “Company,” a molecular genetics diagnostics firm focused on early cancer detection, is pleased to announce its upcoming participation in the Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions. These events are organized by the World Endoscopy Organization (WEO) and are scheduled for October 3rd, 2025, in Berlin, Germany.
This significant gathering unites global leaders in colorectal cancer screening to assess emerging technologies, exchange scientific insights, and help shape future strategies for the early detection and prevention of CRC. During the session entitled “Evaluation of New Tests,” Dr. Lena Krammes, a Senior Scientist at Mainz Biomed, will present findings from the Company’s ongoing research in RNA-based diagnostics.
Dr. Krammes’ presentation, titled “From Detection to Prevention – Early Evidence from RNA-based Screening Test for Precancerous Lesions Compared to Different FIT Cut-offs,” will feature clinical data from the eAArly DETECT study, collected in 2024. This data underscores the potential of stool RNA testing to identify both colorectal cancer and precancerous lesions. Key findings include:
- 97% sensitivity and 97% specificity for detecting colorectal cancer
- 82% sensitivity for advanced adenomas
- 100% detection of advanced adenomas with high-grade dysplasia
These outcomes highlight the capacity for RNA-based testing to play a vital role not only in the early detection of CRC but also in its prevention, by identifying high-risk lesions before cancer development.
Mainz Biomed’s involvement demonstrates its dedication to contributing to global efforts aimed at improving CRC screening outcomes. The World Endoscopy Organization is a global non-profit entity committed to advancing high-quality endoscopy and digestive health. Through its Colorectal Cancer Screening Committee, WEO actively promotes CRC screening activities worldwide and supports the implementation of screening programs, encompassing fecal immunochemical tests (FIT), other stool-based tests, and endoscopic procedures.
“We are honored to participate in this distinguished meeting,” stated Guido Baechler, CEO of Mainz Biomed. “The invitation to engage in these expert discussions affirms our belief that we are making significant contributions towards developing effective, next-generation screening tools capable of preventing colorectal cancer before its onset.”
For updates, please follow us:
About Mainz Biomed NV
Mainz Biomed develops molecular genetic diagnostic solutions for life-threatening conditions that are ready for market. The Company’s primary product is ColoAlert®, an accurate, non-invasive, and user-friendly diagnostic test for the early detection of colorectal cancer. ColoAlert® is currently marketed across Europe. The Company is presently conducting its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study to secure US regulatory approval. Mainz Biomed’s product candidate pipeline also includes PancAlert, an early-stage pancreatic cancer screening test utilizing real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit or follow us on , and .
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
For investor inquiries, please contact
Forward-Looking Statements
Certain declarations within this press release constitute “forward-looking statements” as defined by the “safe harbor” stipulations of the Private Securities Litigation Reform Act of 1995. Such statements are often recognized by terms like “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project,” along with similar phrases that foresee or suggest future occurrences or trends, rather than historical facts. These forward-looking statements are based on the current evaluation of available data and are subject to various risks and uncertainties. Consequently, reliance on these statements requires prudence. Due to identifiable and unforeseeable risks, actual outcomes may substantially diverge from the Company’s anticipated results or forecasts. Among other things, the following elements could lead to actual results differing significantly from those mentioned in these forward-looking statements: (i) an inability to achieve planned development and associated objectives; (ii) alterations in relevant laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its existing or prospective markets; and (iv) other risks and uncertainties detailed herein, as well as those periodically discussed in other reports and public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Further details regarding these and other factors that could influence the Company’s expectations and forecasts are available in its initial SEC filings, including its annual report on Form 20-F submitted on March 31, 2025. The Company’s SEC filings are publicly accessible on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release reflects only the information currently at Mainz Biomed’s disposal and is valid solely as of its creation date. Mainz Biomed assumes no obligation to publicly update any forward-looking statement, whether written or verbal, that may be issued periodically, whether due to new information, future developments, or otherwise, except where legally mandated.
